Purdue Institute for Cancer Research shared a post on LinkedIn:
“Pluvicto’s reach has expanded.
And with it, the impact of a Purdue invention becomes even greater.
The FDA has expanded approval of Pluvicto to PSMA-positive metastatic hormone-sensitive prostate cancer, nearly doubling the eligible patient population. The therapy was invented through research led by Purdue scientist and cancer institute member Philip Low, whose scientific legacy continues to change the treatment landscape for prostate cancer patients.”
Other posts about Purdue Institute for Cancer Research on OncoDaily.